Inflammatory Markers, Myeloproliferative Disease
Conditions
Brief summary
This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated / blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratification
Interventions
None listed
Sponsors
University of Milano Bicocca
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years at the time of diagnosis of MPN Ph negative * Diagnosis of PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000) * Obtaining informed consent
Exclusion criteria
* Life expectancy of less than 6 months * Accelerated phase myelofibrosis or MPN with signs of leukemic evolution
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CBC with leukocyte formula and calculation of the NLR and PLR ratio | 60 months | — |
| Occurrence of arterial and venous thrombotic events | 60 months | type of event, time to event after diagnosis, during illness |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of new and conventional inflammatory biomarkers | 60 months | at the occurrence of the transformation in the overt phase from pre-fibrotic phase in the setting of myelofibrosis or at the occurrence of the evolution of the MPN Ph negative disease in an accelerated and / or leukemic phase or after 6 months from the introduction of conventional cytoreduction or target-therapy ( JAk2 inhibitors) or 6 months after the introduction of inflammatory drugs (iron chelators) |
| Time to thrombo-haemorrhagic events | 60 months | — |
| Time to death and been alive at the end of the study | 60 months | — |
| Time to evolution of the PH negative MPN disease into the fibrotic, accelerated or leukemic phase | 60 months | — |
Countries
Italy
Contacts
Primary ContactElena Maria Elli
Backup ContactBenedetta Valeri
Outcome results
None listed